HomeCompareRDYFF vs ABBV

RDYFF vs ABBV: Dividend Comparison 2026

RDYFF yields 1831.50% · ABBV yields 3.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RDYFF wins by $4390119279.42M in total portfolio value
10 years
RDYFF
RDYFF
● Live price
1831.50%
Share price
$0.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4390119279.52M
Annual income
$3,964,325,134,274,295.50
Full RDYFF calculator →
ABBV
AbbVie Inc.
● Live price
3.09%
Share price
$214.96
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$103.7K
Annual income
$25,324.79
Full ABBV calculator →

Portfolio growth — RDYFF vs ABBV

📍 RDYFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRDYFFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RDYFF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RDYFF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RDYFF
Annual income on $10K today (after 15% tax)
$155,677.66/yr
After 10yr DRIP, annual income (after tax)
$3,369,676,364,133,151.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$262.96/yr
After 10yr DRIP, annual income (after tax)
$21,526.07/yr
At 15% tax rate, RDYFF beats the other by $3,369,676,364,111,625.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RDYFF + ABBV for your $10,000?

RDYFF: 50%ABBV: 50%
100% ABBV50/50100% RDYFF
Portfolio after 10yr
$2195059639.81M
Annual income
$1,982,162,567,149,810.20/yr
Blended yield
90.30%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

RDYFF
No analyst data
Altman Z
-438.1
Piotroski
1/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+19.2% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RDYFF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRDYFFABBV
Forward yield1831.50%3.09%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$4390119279.52M$103.7K
Annual income after 10y$3,964,325,134,274,295.50$25,324.79
Total dividends collected$4359682963.64M$62.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RDYFF vs ABBV ($10,000, DRIP)

YearRDYFF PortfolioRDYFF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$193,850$183,150.18$11,555$434.96+$182.3KRDYFF
2$3,525,522$3,318,102.48$13,485$635.47+$3.51MRDYFF
3$60,170,250$56,397,941.52$15,933$937.67+$60.15MRDYFF
4$963,958,130$899,575,962.05$19,118$1,400.80+$963.94MRDYFF
5$14,500,282,119$13,468,846,920.38$23,384$2,125.24+$14500.26MRDYFF
6$204,865,132,448$189,349,830,579.99$29,290$3,286.81+$204865.10MRDYFF
7$2,719,394,115,485$2,500,188,423,765.96$37,776$5,205.38+$2719394.08MRDYFF
8$33,926,271,547,904$31,016,519,844,335.39$50,495$8,488.44+$33926271.50MRDYFF
9$397,938,453,501,790$361,637,342,945,532.60$70,497$14,346.44+$397938453.43MRDYFF
10$4,390,119,279,521,211$3,964,325,134,274,295.50$103,718$25,324.79+$4390119279.42MRDYFF

RDYFF vs ABBV: Complete Analysis 2026

RDYFFStock

Newpath Resources Inc., a precious metals exploration company, engages in the exploration and development of mineral properties in Canada. It primarily explores for gold ores. It holds Northshore Gold project located in the Schreiber-Hemlo Greenstone Belt near Thunder Bay; and the Hemlo Eastern Flanks Project. The company also owns a 100% interest in 11 contiguous claims comprising od 233,963 hectares located in Schreiber Area. The company was incorporated in 2006 and is headquartered in Vancouver, British Columbia.

Full RDYFF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this RDYFF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RDYFF vs SCHDRDYFF vs JEPIRDYFF vs ORDYFF vs KORDYFF vs MAINRDYFF vs JNJRDYFF vs MRKRDYFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.